GERON CORP Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss
GERON CORP (GERN) had Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss of $243.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $243.00K.
- 2026-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $215.00K.
- 2025-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $54.00K.
- 2025-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $31.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss |
|---|---|
| 2026-06-30 | $243.00K 10-Q · filed 2026-08-05 |
| 2026-03-31 | $215.00K 10-Q · filed 2026-05-06 |
| 2025-12-31 | $54.00K 10-Q · filed 2026-08-05 |
| 2025-09-30 | $31.00K 10-Q · filed 2025-11-07 |
| 2025-06-30 | $66.00K 10-Q · filed 2025-08-06 |
| 2025-03-31 | $41.00K 10-Q · filed 2025-05-07 |
| 2024-12-31 | $191.00K 10-K · filed 2026-03-02 |
| 2024-09-30 | $4.00K 10-Q · filed 2024-11-07 |
| 2024-06-30 | $511.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | $314.00K 10-Q · filed 2024-05-02 |
| 2023-12-31 | $211.00K 10-K · filed 2025-02-27 |
| 2023-09-30 | $972.00K 10-Q · filed 2023-11-02 |
| 2023-06-30 | $980.00K 10-Q · filed 2023-08-03 |
| 2023-03-31 | $280.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $247.00K 10-K · filed 2024-02-28 |
| 2022-09-30 | $644.00K 10-Q · filed 2022-11-07 |
| 2022-06-30 | $801.00K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $712.00K 10-Q · filed 2022-05-09 |
| 2021-12-31 | $177.00K 10-K · filed 2023-03-16 |
| 2021-09-30 | $38.00K 10-Q · filed 2021-11-09 |
| 2021-06-30 | $59.00K 10-Q · filed 2021-08-16 |
| 2021-03-31 | $34.00K 10-Q · filed 2021-05-10 |
| 2020-12-31 | $33.00K 10-K · filed 2022-03-10 |
| 2020-09-30 | $13.00K 10-Q · filed 2020-11-05 |
| 2020-06-30 | $73.00K 10-Q · filed 2020-08-06 |
| 2019-12-31 | $25.00K 10-K · filed 2021-03-11 |
| 2019-09-30 | $23.00K 10-Q · filed 2019-11-06 |
| 2019-06-30 | $7.00K 10-Q · filed 2019-08-01 |
| 2019-03-31 | $37.00K 10-Q · filed 2019-05-02 |
| 2018-12-31 | $212.00K 10-K · filed 2020-03-12 |
| 2018-09-30 | $176.00K 10-Q · filed 2018-11-01 |
| 2017-12-31 | $211.00K 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |